Radu Jacob, MD
Nephrology · Coral Springs, FLNPI 1265462873
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.4%), travel and lodging and education — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by CSL Behring at 44.0% of the total. Reporting peaked in 2024 at $2,533 and has fallen 83.8% since, to $409 in 2025.
Across 112 payments — averaging $39.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$2K
- Amgen$587
- Bayer$448
- GSK$188
- Boehringer Ingelheim$131
- Calliditas Therapeutics US Inc.$128
- plus $1K from 18 others
Across 494 payments — averaging $1796.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$571K
- Vertex$164K
- Astrazeneca UK Limited$58K
- AstraZeneca$41K
- Travere Therapeutics, Inc.$32K
- Ardelyx, Inc.$14K
- plus $8K from 2 others
What the payments were for
- Travel & lodging$1,79040%
- Food & beverage$2,65759%
- Education$291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 9 | $1,968 |
| Amgen(2 entities) | 27 | $587 |
| Bayer | 19 | $448 |
| GSK | 7 | $188 |
| Boehringer Ingelheim | 6 | $131 |
| Calliditas Therapeutics US Inc. | 3 | $128 |
| ANI Pharmaceuticals, Inc. | 4 | $112 |
| Otsuka America Pharmaceutical, Inc. | 5 | $109 |
| AstraZeneca(2 entities) | 5 | $108 |
| Travere Therapeutics, Inc. | 4 | $105 |
| Akebia Therapeutics Inc | 2 | $89 |
| Novo Nordisk | 3 | $80 |
| Nxstage Medical, Inc. | 1 | $58 |
| Xeris Pharmaceuticals, Inc. | 3 | $51 |
| Aurinia Pharma U.S., Inc. | 2 | $45 |
| Vifor Pharma, Inc. | 2 | $45 |
| Shire North American Group Inc | 2 | $41 |
| Novartis | 2 | $38 |
| Mallinckrodt Hospital Products Inc. | 1 | $35 |
| Cvrx, Inc. | 1 | $33 |
| Shield Therapeutics Inc | 1 | $24 |
| Fresenius USA Marketing, Inc. | 1 | $18 |
| Invivyd Inc | 1 | $18 |
| Sanofi | 1 | $17 |
How this compares
$4,475 in reported general payments places this provider in the 75th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 129 | $100,866 |
| KerendiaFinerenone | 101 | $90,834 |
| JardianceEmpagliflozin | 74 | $55,840 |
| VelphoroSucroferric Oxyhydroxide | 13 | $22,035 |
| OzempicSemaglutide | 11 | $21,525 |
| LokelmaSodium Zirconium Cyclosilicate | 23 | $21,025 |
| EntrestoSacubitril/Valsartan | 26 | $17,623 |
| SpsSodium Polystyrene Sulfon/Sorb | 12 | $2,377 |
| Sevelamer Carbonate | 17 | $2,026 |
| Labetalol Hcl | 79 | $1,879 |
| Nifedipine ErNifedipine | 32 | $1,244 |
| Midodrine Hcl | 16 | $1,075 |
| Allopurinol | 77 | $993 |
| Methenamine Hippurate | 14 | $719 |
| Losartan Potassium | 118 | $706 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $108 | $121,891152 claims |
| BayerKerendia | $448 | $90,834101 claims |
| Boehringer IngelheimJardiance | $131 | $55,84074 claims |
| Fresenius USA Marketing, Inc.Velphoro | $18 | $22,03513 claims |
| Novo NordiskOzempic | $80 | $21,52511 claims |
| NovartisEntresto | $38 | $17,62326 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $112 | $19312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 756 nephrology providers in Florida.
Other nephrology in Coral Springs
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
- Jorge LarranagaKissimmee$825K
- Carlos BejarFort Lauderdale$530K
- Wayne KotzkerFort Lauderdale$472K
- Jason RothschildTemple Terrace$413K
- Daniel PatelDaytona Beach$227K
- Rafael Baez BonillaFort Lauderdale$175K
- Gabriel ContrerasMiami$133K
- Fouad ChebibJacksonville$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.